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   Abstract
We describe five children who died of  clinical rabies in a three month 
period (September to November 2011) in the Queen Elizabeth Central 
Hospital.  From previous experience and hospital records, this number 
of  cases is higher than expected.  We are concerned that difficulty in 
accessing post-exposure prophylaxis (PEP) rabies vaccine may be partly 
responsible for this rise.  We advocate:                                                                                  
(a) prompt course of  active immunisation for all patients with significant 
exposure to proven or suspected rabid animals.  (b) the use of  an 
intradermal immunisation regime that requires a smaller quantity of  
the vaccine than the intramuscular regime and gives a better antibody 
response. (c) improved dog rabies control measures
Introduction
Rabies virus is one of  the lyssaviruses and causes an acute 
viral encephalomyelitis that is invariably fatal.  Worldwide, 
there are estimated to be over 10 million human exposures to 
rabies with approximately 55,000 rabies deaths a year, almost 
half  of  which occur in Africa.  These pose a significant 
public health burden with an estimated annual cost of  
$583.5 million and deaths from rabies being responsible for 
an estimated 1.74 million disability-adjusted life years lost 
each year.1 Transmission is through the saliva of  an infected 
animal introduced usually via a bite penetrating the skin. 
Dogs are the most common source, accounting for 96% of  
human rabies cases.2   The virus may also be transmitted by 
wild animals such as bats, foxes and wolves.  The incubation 
period in humans is generally between 3-8 weeks but is 
highly variable and has been described from a few days up 
to several years in rare cases.  In contrast, signs of  rabies in 
animals usually develop within 4-7 days.3  
There are two main clinical presentations in humans: furious 
and paralytic rabies.  Furious rabies accounts for nearly two-
thirds of  cases.  It is characterised by fever, pain or parasthesia 
at the site of  the bite, fear and apprehension, agitation, aero 
and hydrophobia involving spasms of  the muscles involved 
in swallowing and late signs of  delirium, reduced conscious 
level and occasionally seizures.  Paralytic rabies causes 
paralysis of  the limbs and respiratory muscles.  Consciousness 
is not depressed although aero and hydrophobia can be seen. 
Death is usually secondary to respiratory and cardiac failure4. 
The hydrophobia can be especially distressing as the patient 
becomes progressively thirsty and therefore we advocate the 
use of  intravenous fluids in the palliation of  these patients.   
Case Reports
The following patients presented to Queen Elizabeth Central 
Hospital, Blantyre between September and November 2011 
with clinical rabies encephalopathy:
Case 1:  A 9 year old boy, previously fit and well, presented 
with a two day history of  shoulder/neck and abdominal pain 
and a one day history of  difficulty in swallowing.  There was 
a history of  a dog-bite 6 months previously on the right 
hand.  On admission we were told that he had received a full 
course of  post-exposure rabies vaccine but it later transpired 
that although his mother had taken him to the local health 
centre for treatment, there was no vaccine available. 
Although he demonstrated laryngeal spasms on drinking 
water i.e. hydrophobia, there was no aerophobia and he was 
not agitated.  There was no further deterioration during the 
two-day admission and so following discussion with his 
family he was discharged home with instructions to return 
if  he became more unwell.  He returned after seven days 
with obvious signs of  rabies encephalitis including agitation, 
drooling, hydrophobia and aerophobia.  He was started on a 
diazepam infusion and intravenous fluids and died less than 
24 hours after this second admission. 
Case 2: A 9 year old boy with a history of  cerebral palsy 
following meningitis at six months of  age presented with 
new onset lower limb flaccid paralysis for one day and signs 
of  acute confusion, hydrophobia and aerophobia.  There 
was history of  a dog bite 6 months previously.  He was 
seen by the palliative care team and started on a diazepam 
infusion and intravenous fluids.  He became increasingly 
more agitated and confused and died on day 5 of  admission. 
Case 3: A 14 year old girl, previously fit and well, presented 
with a two day history of  painful right arm followed by a one 
day history of  acute agitation and a painful throat.  She had 
been bitten on her right arm by a dog 4 months previously. 
The dog had been killed at the time of  the bite.  She had 
presented to her local hospital but as there were inadequate 
ampoules of  rabies vaccine, this was shared out between a 
total of  three patients and she only received 3 intramuscular 
injections.  On initial examination she was mildly agitated 
but could be settled.  She became increasingly confused 
with signs of  hydrophobia and excessive salivation.  She was 
started on a diazepam infusion and intravenous fluids and 
died 8 hours following admission.  
Case 4:  A 3 year old boy presented with a two day history 
of  fever and one day history of  agitation.  On examination 
he had frank signs of  rabies encephalitis i.e. obvious 
hydrophobia and aerophobia.  There was no history of  dog-
bite and on examination no dog-bite scar.  He deteriorated 
rapidly and died 3 hours after admission.  Despite lack of  
history of  exposure,, his clinical presentation was agreed 
by more than two experienced health professionals to be 
consistent with rabies infection.  It was postulated that he 
may have been licked in the mouth and nose by a rabid dog 
as at his young age we would expect a mother to know if  he 
had been bitten.
Case 5: A 6 year old boy presented with a 12 hour history of  
priapism.  A sickle cell solubility test was negative.  He was 
started on analgesia, antibiotics and intravenous fluids.  He 
was reviewed by the surgeons but his priapism had started 
to resolve and a surgical intervention was not required. 
On day 3 of  admission, the patient developed confusion, 
hydrophobia and aerophobia.  His mother reported a history 
of  a dog bite a month ago.  He had not received anti-rabies 
vaccine.  He was started on a diazepam infusion and died the 
next day.
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Discussion
The estimated normal incidence of  rabies seen in the 
paediatric department at Queen Elizabeth Central Hospital 
is approximately five cases/year.  In the last year we have 
recorded a total of  12 clinical cases of  rabies in children, 9 
of  whom have presented since July 2011 i.e. in a 5 month 
period.  The cases we have seen are likely to represent a much 
larger overall number of  rabies cases in Southern Malawi as 
it has been demonstrated that current reporting systems in 
Africa significantly under-estimate true incidence5.    Active 
surveillance in Tanzania found up to a 100-fold increase of  
rabies deaths when compared to official reported cases6. 
Similar rates have been estimated throughout Africa.1  We 
also know that some patients with rabies infection in Malawi 
are misdiagnosed as other infections such as cerebral malaria7. 
Diagnosing paralytic rabies clinically may be particularly 
difficult.   The paediatric population is most at risk with 40% 
of  PEP (Post Exposure Prophylaxis) vaccine being given to 
children aged 5-14 years9.   Also children tend to be bitten 
more frequently on the head, face and neck which carries the 
greatest risk of  rabies transmission.1,6,10
The most effective and cost-effective strategy of  reducing 
rabies incidence is the control of  dog populations and 
mass rabies vaccination of  dogs2,6.  This needs  consistent 
advocacy in countries such as Malawi where rabies is 
endemic.  Evidence shows that mass vaccination of  domestic 
dogs within Africa is feasible and cost-effective in preventing 
human rabies cases11. The rise in cases suggests that dog 
control measures are inadequate.  
All clinical cases of  human rabies represent either a failure 
to recognise the exposure to a rabid dog and/or absent or 
inadequate PEP which if  administered correctly is highly 
effective at preventing rabies infection12.   From experience 
within our own institution and reports from local health 
centres, rabies vaccine is often not available, or very difficult 
to access, when patients present with a history of  dog bite. 
One of  our cases failed to obtain vaccine despite visiting the 
local health centre, and another child received an incomplete 
course of  vaccine.  It is unacceptable that children are 
succumbing to a devastating and fatal disease when the risk 
has been identified but an effective preventative treatment 
has failed to be administered.
Post-Exposure   Prophylaxis                                                                                                                              
All patients with significant exposure to suspected rabies 
should start rabies PEP as soon as possible.  Exposure 
includes a bite breaking the skin but also saliva in contact 
with mucus membranes or a previous skin lesion where 
the skin barrier has been disrupted (Table 1).  Unprovoked 
bites from an agitated animal (most commonly a dog) are 
obviously a high risk but the animal may also be paralysed or, 
in the case of  wild animals, be unusually tame.  If  in doubt, 
treatment should be started immediately and discontinued 
if  the animal is still healthy after 10 days.  While it may be 
necessary to provide a vet’s certificate confirming clinical 
rabies infection of  the animal in order to continue the full 
course of  post-exposure vaccination, this should not delay 
initiation of  treatment.  If  the animal cannot be identified, the 
full course must be given. Current post-exposure treatment 
includes immediate good irrigation of  the wound with soap 
and water and the application of  iodine.  The wound should 
not be sutured if  possible.  Bacterial infection should be 
treated with antibiotics and tetanus immunisation given if  
appropriate.  Rabies immunoglobulin is recommended if  the 
bite is high risk but is currently unavailable in Malawi and 
most of  the developing world.  Active immunisation with 
rabies vaccine should be started as soon as possible after the 
exposure.  There are a number of  PEP schedules approved 
by WHO using concentrated and purified cell culture (CCV) 
or embryonated egg based (EBV) vaccines.  Nerve tissue 
vaccines are no longer recommended.8  The most commonly 
used regime is the Essen 5 intramuscular (IM) injections of  
one ampoule (0.5ml or 1ml depending on type of  vaccine) 
given into the deltoid muscle or anterolateral thigh on days 
0,3,7,14 and 28.3  However there is good evidence to support 
the use of  intradermal (ID) regimes which use sixty percent 
less vaccine per course compared to IM regimes as each ID 
injection uses only 0.1ml of  vaccine13,14. If  ID injections are 
given, vials can be shared between patients although once 
reconstituted the vaccine must be used within 6-8 hours. 
Even taking into account potential vaccine wastage for 
health centres with few patients requiring PEP, ID regimes 
are estimated to cost two-thirds less than IM regimes.2  ID 
regimes have also been shown to have as much, if  not 
more, effective immunogenicity as IM regimens  and have 
been used successfully in countries such as Thailand and Sri 
Lanka as the primary PEP regime.2  The ID regime currently 
recommended by WHO is the 2-site regimen15 (updated 
Thai Red Cross regimen) which involves giving two 0.1ml 
intradermal injections at two sites (deltoid and thigh) on 
days 0,3,7 and 28.  The additional dose given on day 90 
was dropped following evidence of  efficacy without this 
additional booster16.   More recently, a 4-site ID regimen has 
been shown to be as immunogenic as current ID regimens13 
(4 injections on day 0, 2 injections on day 7 and 28 and an 
optional booster dose on day 90), and a further 1-week 
regimen (4 ID injections on days 0,3 and 7) has also been 
developed.   Both these latter regimens are advantageous 
in reducing the number of  clinic attendances and thereby 
improving compliance and reducing vaccine waste but are 
not yet approved by WHO.  Completing the full course 
of  any rabies vaccine schedule is essential in ensuring full 
protection against the infection and patients and guardians 
should be counselled regarding this; almost ten per cent of  
human rabies cases in India had received incomplete PEP 
vaccination18, while a study conducted in the Ivory Coast 
found 47% of  patients started on PEP failed to complete 
the course of  injections19.                                                    
Our current recommendations for rabies PEP is summarised 
in Figure 1.  Intradermal injections should be given with an 
insulin or Mantoux needle and the injection should raise a 
papule in the skin.  If  the vaccine is given subcutaneously by 
mistake, the dose should be repeated.   
Conclusion
We have seen an increased incidence of  human rabies 
infection in children presenting to the QECH with over 
double the number of  cases we would normally expect to 
see in a one-year period.  This is likely to significantly under-
represent the overall incidence of  rabies cases in Southern 
Malawi and so is of  significant concern.  The most likely 
causes of  this rise are inadequate supply of  anti-rabies 
vaccine and inadequate dog-control measures.  Intradermal 
vaccine regimens are as efficacious as intramuscular 
regimens and will lead to substantial cost savings and use 
of  less vaccine.  This is particularly pertinent in the current 
setting where rabies vaccine is in short supply worldwide and 
we would strongly advocate the use of  ID regimens.  This, 
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together with the recognition of  patients at risk of  rabies 
infection, good wound care and stressing the importance of  
completing the vaccine course requires ongoing education 
and support within the medical community.  In addition, we 
call on the responsible government agencies in Malawi to 
introduce mass dog vaccination campaigns.  Taking these 
steps, combined with ongoing public awareness of  the 
problem should result in the prevention of  this devastating 
illness.
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